Additionally, on December 20, Oliviero transferred 900,000 shares into an irrevocable trust for his minor children. This transfer was executed at no cost, and Oliviero does not have investment control over the securities held by the trust. Following these transactions, Oliviero retains ownership of 2,294,583 shares of Checkpoint Therapeutics (NASDAQ:). InvestingPro subscribers can access additional insights, including 8 more key investment tips and detailed financial health metrics for CKPT. InvestingPro subscribers can access additional insights, including 8 more key investment tips and detailed financial health metrics for CKPT.
Additionally, on December 20, Oliviero transferred 900,000 shares into an irrevocable trust for his minor children. This transfer was executed at no cost, and Oliviero does not have investment control over the securities held by the trust. Following these transactions, Oliviero retains ownership of 2,294,583 shares of Checkpoint Therapeutics.
In other recent news, Checkpoint Therapeutics has been the focus of several significant developments. Earnings per share for the second quarter surpassed both firm and consensus estimates at ($0.18). In addition, the company secured an additional $12 million from a recent offering.
Checkpoint Therapeutics also reported promising results from its cosibelimab trial, with objective response rates surpassing previous observations. The company has set a Prescription Drug User Fee Act goal date for December 28, 2024, for the Biologics License Application for cosibelimab.
Lake Street Capital Markets upgraded Checkpoint Therapeutics’ price target from $4 to $7 while maintaining a Buy rating. The firm expressed confidence in the company’s continued growth into 2025. Meanwhile, H.C. Wainwright reiterated a Buy rating on the stock, highlighting the potential market opportunity for cosibelimab.
In other company news, Checkpoint Therapeutics announced a stock sale expected to generate approximately $12 million and a partnership with GC Cell to evaluate the combination of their cancer treatments. These are among the recent developments in Checkpoint Therapeutics’ ongoing efforts in the field of immunotherapy and targeted oncology.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
